Skip to main content

Simon Mallal, MBBS, FRACP, FRCPA

  • Major E.B. Stahlman Chair in Infectious Diseases and Inflammation
  • Professor of Medicine (Infectious Diseases)
  • Professor of Pathology, Microbiology and Immunology
  • Director, Center for Translational Immunology and Infectious Diseases

Phone

615-322-2035

Email

s.mallal@vumc.org
1161 21st Avenue South
S2105 Medical Center North
Nashville, TN 37232

Simon Mallal, MBBS, FRACP, FRCPA

  • Major E.B. Stahlman Chair in Infectious Diseases and Inflammation
  • Professor of Medicine (Infectious Diseases)
  • Professor of Pathology, Microbiology and Immunology
  • Director, Center for Translational Immunology and Infectious Diseases

615-322-2035

s.mallal@vumc.org

1161 21st Avenue South
S2105 Medical Center North
Nashville, TN 37232

Research Program

  • Non-Programmatically Aligned

Profile

Dr. Mallal completed his training in Internal Medicine, Clinical Immunology and Pathology and led the development of HIV services and one of the first computerized cohort studies in Western Australia before undertaking a post-doctoral fellowship in Infectious Diseases at Johns Hopkins Medical School. He has undertaken clinical practice management altering research throughout his career which has informed and directed his basic science research. This has had impacts over time in the domains of: reproductive endocrinology (1978 - 82), genetic disease association studies (1987 - present), immune restoration disease in HIV (1994 onwards), improved efficacy of antiretroviral therapy (1988 onwards), mitochondrial toxicity and metabolic complications of antiretroviral therapy (1997 on), use of pharmacogenetic tests to avoid drug hypersensitivity (2002 on) and HIV and Hepatitis C adaptation to HLA restricted immune responses to support vaccine immunogen design and potential eradication approaches. His group discovered the association between HLA-B*5701 and abacavir hypersensitivity in 2002 and he and his colleagues championed the international collaborative efforts to guide pharmacogenetic screening through the T1 to T4 phases of translation over the next 7 years. The impact on clinical and healthcare practice and policy in these domains has been important, as has the development of new multidisciplinary capacity and approaches to translational medicine. This culminated in the establishment of a purpose-built translational medicine Institute in Western Australia which he leads.

He has authored over 200 articles and book chapters and given over 215 presentations at scientific meetings. He serves on several international scientific committees and advisory boards, received the Western Australian Premiers Science Award in 2006 and is a member of the Association of American Physicians.

He first visited Vanderbilt as a Pfizer Visiting Professor in 2002 and continued to actively collaborate with colleagues here until he joined the Faculty in 2013.


Education

  • M.B.B.S., University of Western Australia, Perth, Australia (1983)
Postgraduate Training
  • FRACP Internal Medicine and Clinical Immunology and Allergy), Royal Australian College of Physicians, 1989
  • FRCPA (Immunopathology) Royal Australian College of Pathologists, 1990
  • Post-doctoral Fellowship in Infectious Diseases, Johns Hopkins Medical Institutions, 1994


Research Emphasis

Research Description

Publications

Have any questions? Contact Us 1-877-936-8422 for more information